Cancer stem cells (CSCs) drive recurrence and resistance, evading standard therapies through iron-rich metabolism and ...

A first-in-human phase 1 trial of the Fc-enhanced CD40 agonist antibody 2141-V11 has shown striking results: six of 12 ...

The FDA has granted accelerated approval to Wegovy® (semaglutide) as the first treatment for MASH with moderate-to-advanced ...

Researchers have identified RUNX1C, an RNA isoform that drives chemoresistance in acute myeloid leukemia (AML). The study, ...

Researchers have developed a novel cancer therapy using Salmonella typhimurium to deliver an oncolytic virus directly into ...

A novel mRNA-based vaccine encoding tumor-specific neoantigens significantly enhanced anti-PD-1 therapy in gastric cancer ...

FDA approved Papzimeos (zopapogene imadenovec), the first-in-class, non-replicating adenoviral vector-based immunotherapy, ...

New findings, published in Cellular and Molecular Gastroenterology and Hepatology, show that the transcription factor CREB ...

The Phase 3 EV-303 (KEYNOTE-905) trial shows PADCEV™ (enfortumab vedotin) plus KEYTRUDA™ (pembrolizumab) is the first and only regimen to significantly extend event-free and overall survival when used ...